Background: Hemophilia is the most frequent severe hereditary hemorrhagic disease due to deficiency of coagulation factors VIII (Hemophilia A) or IX (Hemophilia B) in plasma. We aimed to identify patients with  hemophilia in Kermanshah, Iran and assess the incidence of inhibitors in this population and its associated factors. Methods: This study was conducted on patients with hemophilia...

introduction: haemophilia a is the most common inherited x-linked recessive bleeding disorder. the severity of the resultant bleeding diathesis depends on the fviii levels associated with the mutation. analysis of carrier state can be made indirectly by dna linkage analysis or directly by identifying the mutation that leads to the disease. the aim of this study was to identification of the caus...

TUI)IES OF HEMOPHILIA have, ins the past-, helped greatly to solve the mansy intricacies of the blood coagulation mechanism. More recently, howeser, they have also altered our s-cry (‘onscept of the disease arid stnggested that, ins-stead of a svehl defined entity, hemophilia ins fact represents a syndrome siit.h many different pathogensetic mechanisms. The questions “ i’hat. is hemophihia?” is...

bypassing agents are the most commonly used medicines for the treatment of hemophilia patients with inhibitors. the aim of this study is to identify the cost components of management of bleeding vents in hemophilia patients with inhibitors in iran. this study is a cross-sectional study using a bottom-up approach to determine the cost components of treatment of hemophilia patients with inhibitor...

If a woman is a carrier there is a 1 in 2 chance that any son will be affected and a 1 in 2 chance that any daughter will be a carrier. If a man with the disease fathers a child, any daughter will be a carrier and any son will be unaffected and will not carry the gene. There is a report of a daughter of a man with the disease who had a factor IX level of 5% and haemarthroses and this was though...

Correction The list of authors of this article [1] was incorrect as published and should be as follows: Theodoros Kelesidis, Jonelle Raphael and Elizabeth Blanchard. Rekha Parameswaran did not approve the final version of the manuscript for publication and does not wish to be included as an author. In addition, Elizabeth Blanchard’s initials appeared incorrectly as BE in the authors’ contributi...

BACKGROUND In 1975, a national network of hemophilia treatment centers (HTCs) was created to increase access to healthcare services for individuals with hemophilia. Studies demonstrate that care in HTCs improves outcomes and reduces costs. PURPOSE The objective of the study was to assess the association of demographic, insurance, and clinical characteristics with self-reported barriers to HTC...

In this issue of Blood, Astermark et al have identified novel genetic markers of inhibitory antibody formation in hemophilia patients that may ultimately lead to prediction and even prevention of this severe complication of hemophilia treatment.(1)